The Further, Faster Podcast

Future Fields uses engineered fruit flies to manufacture recombinant proteins at lower cost than traditional bioreactors

41 min Listen to the original Episode page
BiomanufacturingDeep TechContract ManufacturingSynthetic BiologyVenture CapitalAgriTechPharmaceuticalsCanada Startups

Summary

Matt Anderson-Baron, founder of Future Fields, explains how the company pivoted from cultured meat to contract manufacturing using genetically engineered Drosophila melanogaster as living bioreactors. He argues that traditional E. coli and yeast systems face physical limitations and high contamination risks, whereas insect systems offer inherent immunity and lower costs. Anderson-Baron highlights a 2026 market bottleneck where AI-designed proteins outpace physical validation, creating demand for high-throughput manufacturing services. The company leverages Edmonton's low costs and government funding to scale modularly, aiming to enable one billion lives impacted by novel bioproducts by 2035.

Key takeaways

  1. 1
    I mean, our our big Here Harry Audacious goal, like our 2035. goal is to positively impact a billion lives by enabling novel products to reach the market.

    Unidentified speaker (speaker_0) · 39:11

Episode sections

  1. 0:00 – 2:29

    Intro and Disclaimer

    Speaker 0 questions the stagnation of biomanufacturing using E. coli and yeast. Speaker 2 provides a standard Antler disclaimer. Speaker 1 introduces the podcast and guest Matt Anderson-Baron of Future Fields.

  2. 2:29 – 9:37

    Origin Story: Cultured Meat and Growth Factors

    Matt Anderson-Baron explains starting Future Fields in 2017 during his PhD at the University of Alberta. The company initially aimed to solve the high cost of growth factors for cultured meat, exemplified by a 20-gram chicken nugget prototype.

  3. 9:37 – 12:48

    Pivot to Contract Manufacturing

    Future Fields pivoted from cultured meat to a contract manufacturing model for recombinant proteins. This shift was driven by regulatory and consumer headwinds in the cultured meat sector and the realization that protein manufacturing challenges were pervasive across industries.

  4. 12:48 – 16:12

    Technology and Advantages of Insect Biofactories

    The company uses genetically engineered fruit flies (Drosophila melanogaster) as living bioreactors. This approach offers lower costs, higher scale, and resilience to contamination compared to traditional single-cell bioreactors, as insects have immune systems.

  5. 16:12 – 18:58

    Market Applications and Rescue Programs

    Future Fields serves agrosciences, pharmaceuticals, and industrial applications. A key use case is 'rescue programs' where clients face 400-week delays in producing proteins for regulatory studies, which Future Fields aims to accelerate.

  6. 18:58 – 24:47

    Founder Evolution: Scientist to CEO

    Matt Anderson-Baron discusses transitioning from a lab-focused scientist to a CEO. He learned to stop obsessing over technology perfection and start focusing on customer problems, hiring a team that complements his 'ship it' mentality with rigorous quality checks.

  7. 24:47 – 28:16

    Y Combinator Experience

    The company joined Y Combinator in 2020 as the first remote batch. This provided critical exposure to the Silicon Valley investor community, resulting in 82 investor meetings in 13 days post-demo day, which was pivotal for raising capital.

  8. 28:16 – 30:46

    Edmonton Advantages

    Anderson-Baron highlights Edmonton's advantages for deep tech: cheap space ($12/sq ft for 20,000 sq ft), lower payroll costs due to cost of living, high talent density from local universities, and significant non-dilutive government funding.

  9. 30:46 – 31:10

    Government Support and Funding

    Matt Anderson-Baron states that Future Fields' manufacturing site received support from federal, provincial, and municipal governments. He notes that leveraging these numerous government programs was critical to the company's current position.

  10. 31:10 – 32:00

    AI Design vs. Physical Manufacturing Bottleneck

    Speaker 1 asks if AI-accelerated protein design will outpace physical manufacturing capabilities. Anderson-Baron confirms that in 2026, designing a protein is easier than expressing or making it, creating a bottleneck in wet lab validation and a tailwind for manufacturing companies.

  11. 32:00 – 33:12

    Strategic Pivot to High-Throughput Services

    Anderson-Baron explains that Future Fields' existing large-scale, low-cost technology is not ideal for high-throughput, small-scale validation needs. The company is developing new technology to address this gap, with promising initial results.

  12. 33:12 – 34:39

    Market Expansion and Legacy Comparison

    The speaker describes the market for protein expression as endless, noting their system is six years old compared to legacy platforms that are ten times older. They are focusing on developing high-throughput, small-scale protein expression capabilities for drug development and agri-sciences.

  13. 34:39 – 37:31

    Modular Facility Scaling in Edmonton

    Anderson-Baron contrasts software scaling with biomanufacturing, explaining that Future Fields uses a modular approach. Instead of building new facilities, they add modules to their existing 'Instar' biofactory in Edmonton, focusing on upstream insect rearing which is less costly than downstream sterile processing.

  14. 37:31 – 41:11

    Science vs. Industrialization Challenges

    When asked what is harder, Anderson-Baron states it depends on the project. Some programs face scientific challenges in protein solubility and purification, while others face industrial challenges in scaling to customer quantities. He asserts the technology was built for industrial scale, making scaling seamless once the science is solved.

Claims worth verifying

Recombinant technology was first developed over 50 years ago, yet the industry still primarily uses E. coli, yeast, and mammalian cells.

Unidentified speaker (speaker_0) ·0:00

How to verify: Review historical literature on recombinant DNA technology development (e.g., 1970s milestones) and current industry standards for protein production. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.

Future Fields was started in late 2017 by Matt Anderson-Baron, a PhD student at the University of Alberta.

Unidentified speaker (speaker_0) ·2:31

How to verify: Check University of Alberta alumni records or Future Fields corporate history/press releases for founding date and founder affiliation. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.

The company created a 20-gram cultured chicken nugget prototype using a primary cell line from a broiler chicken.

Unidentified speaker (speaker_0) ·4:34

How to verify: Search for academic publications or press coverage from 2026-2026 regarding University of Alberta cultured meat prototypes and Future Fields' early history. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.

Growth factors are the primary cost driver in cultured meat production.

Unidentified speaker (speaker_0) ·5:53

How to verify: Review industry reports on cultured meat cost structures (e.g., from Good Food Institute or academic journals) comparing growth factor costs to other inputs. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.

Future Fields utilizes Drosophila melanogaster (fruit flies) as industrial biofactories for recombinant proteins.

Unidentified speaker (speaker_0) ·8:19

How to verify: Check Future Fields' website, patents, or scientific publications detailing their insect-based biomanufacturing process. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.

A client in the agrosciences space faces a 400-week delay in producing proteins for regulatory studies using traditional methods.

Unidentified speaker (speaker_0) ·17:34

How to verify: Review regulatory guidelines for GM crop approval (e.g., from USDA, EPA, or EFSA) and industry case studies on protein production timelines for toxicity testing. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.

Future Fields has approximately 40 employees.

Unidentified speaker (speaker_0) ·24:00

How to verify: Check LinkedIn company page for Future Fields or recent press releases for employee count. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.

Future Fields occupies 20,000 square feet of space in Edmonton at a cost of $12 per square foot.

Unidentified speaker (UNKNOWN) ·29:13

How to verify: Review commercial real estate listings or company disclosures regarding their Edmonton facility lease terms. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.

The company had 82 investor meetings in 13 days after Y Combinator Demo Day.

Unidentified speaker (speaker_0) ·27:01

How to verify: Cross-reference with Y Combinator Demo Day records or investor meeting logs if publicly disclosed; verify via press coverage of the 2026 YC batch. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.

Future Fields is based in Edmonton, Canada.

Unidentified speaker (speaker_1) ·1:41

How to verify: Check company registration records or official website for headquarters location. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.

Future Fields' manufacturing site was supported by federal, provincial, and municipal governments.

Unidentified speaker (speaker_0) ·30:46

How to verify: Check government grant databases (e.g., Canada's Strategic Innovation Fund, Alberta Innovates, City of Edmonton grants) for awards to Future Fields between 2026-2026. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.

In 2026, it is easier to design a protein than to express or make it.

Unidentified speaker (speaker_0) ·31:41

How to verify: Review industry reports on AI protein design (e.g., AlphaFold, RFdiffusion) vs. wet lab throughput data from contract manufacturing organizations (CMOs) for 2026. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.

Future Fields' existing technology is not a good fit for high-throughput, small-scale validation needs.

Unidentified speaker (speaker_0) ·32:40

How to verify: Review Future Fields' product portfolio or technical whitepapers to distinguish between their large-scale commercial offering and their developing high-throughput R&D offering. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.

Future Fields' system is six years old, while legacy platforms are ten times as old.

Unidentified speaker (UNKNOWN) ·33:19

How to verify: Calculate the founding date of Future Fields (approx. 2026 based on 'six years old' in 2026) and compare to the commercial launch dates of legacy bioreactor platforms (e.g., Thermo Fisher, Sartorius) which date back to the 1970s-1980s. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.

Future Fields is building a biofactory facility called 'Instar' in Edmonton.

Unidentified speaker (speaker_1) ·34:58

How to verify: Search for 'Instar Future Fields Edmonton' in real estate filings, company press releases, or local business registries. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.

Primary source

Downstream processing (sterile clean rooms) is where most facility costs come from, not upstream insect rearing.

Unidentified speaker (speaker_0) ·36:11

How to verify: Review capital expenditure breakdowns in Future Fields' investor presentations or industry benchmarks for biomanufacturing facility costs comparing upstream vs. downstream CAPEX. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.

Future Fields' 2035 goal is to positively impact a billion lives by enabling novel products to reach the market.

Unidentified speaker (UNKNOWN) ·38:58

How to verify: Check Future Fields' official website, mission statement, or latest annual report for the '1 billion lives' metric and 2026 target. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.

Do your own research

  • Verify the technical claims regarding Drosophila melanogaster as a bioreactor platform by reviewing peer-reviewed scientific literature on insect cell culture yields and protein expression efficiency.
  • Check Future Fields' patent portfolio and intellectual property filings to assess the defensibility of their proprietary insect-based manufacturing processes.
  • Analyze the competitive landscape of contract manufacturing organizations (CMOs) like Ginkgo Bioworks, Zymergen, or traditional CDMOs to evaluate market share and pricing pressure.
  • Review the company's financial disclosures or pitch decks for details on government grant dependencies, non-dilutive funding amounts, and runway status.
  • Investigate the regulatory pathway for GM crops and therapeutics requiring the 'rescue programs' mentioned, specifically looking at FDA/USDA timelines for toxicity studies.
  • Assess the scalability claims of the 'Instar' modular facility by reviewing engineering reports or third-party validations of the upstream/downstream processing integration.
  • Examine the founder's background and Y Combinator alumni network for any potential conflicts of interest or biases in the investment thesis presented.
  • Look for counter-arguments from traditional biomanufacturing incumbents regarding the limitations of insect systems for complex mammalian proteins or large-scale industrial production.
Full transcriptexpand
0:00
Unidentified speaker (speaker_0): It's been fifty plus years since recombinant technology was first developed. Why are we still just using E. coli, yeast, and mammalian cells to manufacture the wide variety of proteins that that the markets need? I mean, there's millions, billions, if not more, different proteins that exist out there that need to be made. And so why are we just
0:20
Unidentified speaker (speaker_0): trying to shove them into these three boxes that are really all very similar? They're just single cells grown in in tanks. And so the idea was to come up with a solution that was, you know, fundamentally different. Think outside the tank and think of a solution that didn't require, you know, this costly complex infrastructure
0:39
Unidentified speaker (speaker_0): that really created the limitations of what was possible.
0:48
Unidentified speaker (speaker_2): This content is provided for informational purposes. only and does not constitute legal, business, tax, or investment advice. It does not constitute an invitation or recommendation to purchase or subscribe for, and should not be relied upon when making any investment decision in any Antler fund or any other investment instrument.
1:07
Unidentified speaker (speaker_1): Hi everybody, welcome to Further For Faster the Podcast. My name is Shambhavi and I'm an associate partner with Antler Canada. On this podcast,
1:15
Unidentified speaker (speaker_1): we speak with founders, investors, and builders, tackling the world's hardest problem
1:21
Unidentified speaker (UNKNOWN): and
1:21
Unidentified speaker (speaker_1): then exploring what it takes for them to build their companies from inception to scale. Today's story starts in an unusual place. Imagine you're a scientist trying to grow a piece of meat in the lab, and you realize that the most critical ingredient is primary. prohibitively super expensive.
1:40
Unidentified speaker (UNKNOWN): And
1:41
Unidentified speaker (speaker_1): then you realize that the solution to this problem actually lies in your kitchen, something that you and I are constantly trying to get rid of. Any guesses? Well, it's fruit flies. My guest today is Matt Anderson Barron, co-founder and CEO of Future Fields, an adminton-based biotech company
2:01
Unidentified speaker (speaker_1): that's solving for exactly this problem.
2:04
Unidentified speaker (speaker_1): Matt, welcome to the Further Faster podcast.
2:07
Unidentified speaker (speaker_0): Thank you. So happy to be here.
2:09
Unidentified speaker (speaker_1): Great. We have a lot to unpack today, Matt. So before I jump into what really Future Fields is, let's go all the way back. You weren't actually trying to reinvent protein manufacturing at Future Fields. You were actually doing your PhD and you were trying to grow meat. How did Future
2:29
Unidentified speaker (speaker_1): Field begin?
2:31
Unidentified speaker (speaker_0): Yeah, so I mean, this started back in late 2017. Um, as you said, I was a grad student. I was doing my PhD in cell biology at the University of Alberta. And I was at a stage in my life where I was trying to figure out what comes after school. I'd been uh a student for so for long and was thinking I about career
2:51
Unidentified speaker (speaker_0): options. And while I loved being in the lab and I loved research and I loved, you know, being at the cutting edge of, you know, biology and biotechnology, um, I realized that academia was not for me. Um and so that kind of had me conflicting conflicted about the career choices I had made and what comes
3:11
Unidentified speaker (speaker_0): next. Um and then all of all of a sudden we uh my my co-founder who's also my wife uh sent me a uh a website for New Harvest, which is a nonprofit that supports um funding for the cellular agriculture industry or cultured meat. And I mean I was just
3:31
Unidentified speaker (speaker_0): immediately floored. This was my first exposure to this new this new industry, this new technology. And I thought, you know, this is what I wanted to do. It just checks checked so many boxes for me, um, you know, in terms of the the technology, the bleeding edge, um, a skill set that, or you know, leveraged a skill set that I was developing in
3:50
Unidentified speaker (speaker_0): grad school, but also just resonated with me so personally in terms of the sustainability and building animal welfare. And so I was just like, this is what I want to do. And I mean, again, this was eight years ago, nine years ago now.
4:03
Unidentified speaker (speaker_0): Um, back then the industry was really small and it was it was very nascent and there was a small number of companies, but there really wasn't much going on. And so the only real way to get involved was to start your own company. And so that's what we decided to do. And I don't think we fully appreciated what that meant at the time, was like,
4:20
Unidentified speaker (UNKNOWN): Oh
4:21
Unidentified speaker (speaker_0): yeah, we're gonna start a
4:21
Unidentified speaker (UNKNOWN): company.
4:22
Unidentified speaker (speaker_1): Yeah.
4:23
Unidentified speaker (speaker_0): Um, but that's what what that was the impetus for
4:25
Unidentified speaker (UNKNOWN): for
4:26
Unidentified speaker (speaker_0): you know.
4:26
Unidentified speaker (speaker_1): But
4:27
Unidentified speaker (UNKNOWN): let's let's
4:27
Unidentified speaker (speaker_1): unpack that a little bit. I remember you mentioned that there is a 20 gram chicken nugget story. What was that story?
4:34
Unidentified speaker (speaker_0): Yeah, so th this was so when we got started and decided, you know, hey, we're gonna we're gonna do this. Um my supervisor at the time, he was great. He was really supportive of this idea and he kind of let me tinker in the laps on on evenings and weekends. And so, you know, the first step I at the time, every all the other cultured meat companies were doing was, you know,
4:54
Unidentified speaker (speaker_0): build a prototype. Um, and so for us, prototype was we were going to do a chicken nugget. So I actually went and got uh a muscle sample from a live broiler chicken that was just euthanized from the university campus farm. And uh I was able to establish uh a uh what called a primary uh cell line
5:14
Unidentified speaker (speaker_0): from from that sample. And so I started working with that in the lab. Like I said, evenings and weekends, tinkering. And the idea was to try to create, like I said, a prototype. And so we were successful in in making this this small chicken nuggets. Yeah. Um but that exposed us to the challenge that everybody else in that
5:33
Unidentified speaker (speaker_0): industry was facing then and still are facing is cost is very, very high. And uh the scale is very, very challenging of any bioprocess. And when you're trying to compete with a commoditized product like food or more specifically chicken nuggets, uh that can be a barrier, a pretty considerable barrier. And when we started to dissect
5:53
Unidentified speaker (speaker_0): what the big cost drivers were, it was primarily the things that go into stimulating the cells to grow, which are called growth factors. Growth factors.
6:03
Unidentified speaker (speaker_0): are a type of protein. And these are high value signaling molecules. They're used in a wide variety of industries. But in this case, with this application, there was a demand for really low cost and really large scale production of growth factors. And that is our first exposure to the problem that we're solving today, which is
6:23
Unidentified speaker (speaker_0): protein manufacturing, biomanufacturing of these really important molecules. And the existing systems were just insufficient to meet the demand.
6:32
Unidentified speaker (UNKNOWN): And then how
6:33
Unidentified speaker (speaker_1): did that jump happen where you were like, oh, proteins, growth factor are too expensive,
6:39
Unidentified speaker (UNKNOWN): but
6:39
Unidentified speaker (speaker_1): maybe fruit flies can solve them? When did that unlock happen?
6:44
Unidentified speaker (speaker_0): Yeah, so again, And uh the that exposure to the problem was what set us to start thinking about how to solve it.
6:51
Unidentified speaker (speaker_0): And when we started doing the math uh on how to meet the cost and scale of this new market with the legacy platforms, with the existing technologies, we just
7:05
Unidentified speaker (UNKNOWN): we
7:05
Unidentified speaker (speaker_0): knew it wasn't going to work. Uh, and that's because of the fundamental limitations of those technologies themselves. Primarily, these are genetically engineered cell lines grown in big, costly carbon. complex steel tanks called bioreactors. And so, short of, you know, rewriting the laws of biology and physics, those systems were probably not going
7:25
Unidentified speaker (speaker_0): to get substantially better, not to the point that was, you know, this this market demanded. And so
7:32
Unidentified speaker (speaker_0): when we started thinking about that, it was kind of like, well, why why is it that these are really
7:39
Unidentified speaker (speaker_0): these are the only options? You know, it's it's been 50 plus years since recombinant technology was first developed. Why are we still just using E. coli, yeast, and mammalian cells to manufacture the wide variety of proteins that that the markets need? I mean, there's millions of billions, if not more, different proteins that exist out there that need
7:59
Unidentified speaker (speaker_0): to be made. And so why are we just trying to shove them into these three boxes? that are really all very similar? They're just single cells grown in tanks. And so the idea was to come up with a solution that was, you know, fundamentally different. Think outside the tank and think of a solution that didn't require, you know,
8:19
Unidentified speaker (speaker_0): this costly complex infrastructure Structure that really created the limitations of what was possible. So I came from a fruitful. fruit fly lab. My PhD was in a lab that utilized Drosophila melanogaster as a model organism. And so we had some familiarity with that. But more specifically, my wife, my co-founder, she knew a little bit about it. She wasn't,
8:39
Unidentified speaker (speaker_0): she's not a scientist, at least not a biological scientist. And it was actually her, she she came up with the the sparky idea. was She said, you know, what about fruit flies?
8:50
Unidentified speaker (UNKNOWN): Um
8:50
Unidentified speaker (speaker_0): and while her idea, you know, which was initially to just like use them as a natural source of growth factors isn't what we're doing today, that was the spark of the innovation to say, okay, what about fruit flies and could we turn that from a laboratory model organism into an industrial biofactory? Um and so that
9:10
Unidentified speaker (speaker_0): that's what brought fruit flies into the story and it really started to
9:14
Unidentified speaker (speaker_1): go forward. for it. I I just love this part of the story. And it's because I see this re repeatedly with great companies. You start solving for one problem, then you hit a constraint, and eventually you realize that the constraint itself is bigger, and that becomes the new problem to solve. So let's unpack this a is little bit.
9:34
Unidentified speaker (speaker_1): Explain future fields to me.
9:37
Unidentified speaker (speaker_1): Assume that I know absolutely nothing about bio, biomanufacturing. For example, if I just come to you and I say, hey, future fields, Matt, I want this protein. What actually happens?
9:49
Unidentified speaker (speaker_0): Yeah, so I mean, in short, Future Fields is a biomanufacturing company for recombinant proteins. We have a novel technology that utilizes genetically engineered insects to manufacture recombinant proteins. proteins at lower cost, at larger scale, and uh proteins that struggle to be made in the traditional system. So
10:09
Unidentified speaker (speaker_0): better, faster, cheaper.
10:11
Unidentified speaker (UNKNOWN): Um,
10:11
Unidentified speaker (speaker_0): and so we operate as a contract manufacturer. So clients come to us and say, we need this specific molecule made, uh, and then we develop a process for that in our system in the Into Engine. Um, and then once that process is established, we can scale it up and manufacture.
10:27
Unidentified speaker (speaker_0): commercial quantities using our using our process. So where we got to today from the cultured meat story, I mean, as we as we started to commercialize and as we started to bring our technology to market, we were we were hyper focused on on the cultured meat sector.
10:47
Unidentified speaker (speaker_0): And what we realized quite quickly was that market had a lot of challenges beyond just cost of growth factors. There was, you know, regulatory, there was customer perceptions, there was a scale piece that was irrespective of growth factors. There was, there was a lot of hurdles to clear.
11:09
Unidentified speaker (speaker_0): To believe it just wasn't scaling at the rate that uh we needed it to survive as an or as a company. So we saw pretty early on that we needed to look for other markets and other opportunities to build a viable business. We just weren't going to survive. And
11:23
Unidentified speaker (UNKNOWN): the
11:24
Unidentified speaker (speaker_0): thing we realized uh very quickly was that protein manufacturing, biomanufacturing is a pervasive problem. It's not just a growth factor problem for cultured meat, but I mean it's it exists in in the pharmaceutical space and drug development in. RD in industrial applications. Biomanufacturing and the challenges
11:44
Unidentified speaker (speaker_0): associated with it were so much bigger than than the cultured meat space. So fortunately, you know, there were a lot of other markets and opportunities to go after. And so we we pivoted from, and it wasn't a clean pivot where it was just like an instant decision. There was a lot of learning and iteration and talking to customers and talking to to people in the market. before we got to this
12:04
Unidentified speaker (speaker_0): this current um uh sort of format of the company. But um we we realized that the way we make these molecules is really what makes us unique, not necessarily the the molecules themselves. And so that's what led to the pivot to more of a contract manufacturing model, um, which since doing we've seen seen a lot of positive validation for.
12:23
Unidentified speaker (speaker_1): Yeah. But f just unpacking this here for the audience and I'll definitely come to the constraint that you're solving for and the future of future fields, but unpacking this a little bit, why are fruit fries generally better? Like, give me an example of some protein which the conventional systems are struggling to making, but you have really unpacked. Is there
12:43
Unidentified speaker (speaker_1): something a success that you recently won or something that you've unpacked?
12:48
Unidentified speaker (speaker_0): Yeah, so I mean to touch on that. we we're we're often brought in as a rescue operation. That's kind of how a lot of our commercial relationships start. Um, because again, to date, there's a small number of systems that a small number of options that are available when you want to make a protein.
13:08
Unidentified speaker (speaker_0): And what our customers very often experience is those systems are insufficient to meet their needs. And that could be a variety of reasons. Protein manufacturing is extremely complex.
13:33
Unidentified speaker (speaker_0): There's a lot of different ways that it it can become a challenge. That's intricate. intricately linked to cost as well. It could mean that the cost is
13:43
Unidentified speaker (speaker_0): prohibitively expensive. Or the molecule itself just may be too complex for the biological machinery of those systems because proteins are functional molecules. And function is not binary, it's not on or off, but there's a range of function, and that comes down to how it's expressed, how it folds into its three-dimensional conformation. All that
14:03
Unidentified speaker (speaker_0): dictates the function. And so again, when you try to shove the all these complexities and vasodurations of protein biochemistry into just three boxes, you get a lot of um problems. You get a lot of uh uh uh you know things that don't work. And so our system is about, you know, not just creating
14:23
Unidentified speaker (speaker_0): more optionality, but creating solutions to those. specific challenges that people end up facing. And so why fruit flies? Um, well, it circumvents a lot of those fundamental limitations. Again, we don't use bioreactors. The the insect is a bioreactor. Um, and our infrastructure is very,
14:43
Unidentified speaker (speaker_0): very low cost, very flexible.
14:45
Unidentified speaker (speaker_1): Nature made the bioreactor?
14:46
Unidentified speaker (speaker_0): Yeah, I mean, you can kind of think of it that way.
14:48
Unidentified speaker (UNKNOWN): Like
14:48
Unidentified speaker (speaker_0): billions of years of evolution has created this.
14:52
Unidentified speaker (speaker_0): really great living bioreactor.
14:54
Unidentified speaker (UNKNOWN): Um,
14:55
Unidentified speaker (speaker_0): but you know, even even our infrastructure is like I said, it's very low cost, very flexible. Um, you know, getting into the weeds a little bit, it it it also solves for things like contamination. Yeah.
15:06
Unidentified speaker (speaker_1): When
15:06
Unidentified speaker (speaker_0): you're growing single cells in a bioreactor, contamination is a huge issue because cells don't have an immune system. Any any the smallest amount of bacteria. that are or microbe that can get in there can can wreak havoc on your process. It can it can kill a whole batch. Where our insects, they can handle some
15:26
Unidentified speaker (speaker_0): low-level amount of contamination. They have an immune system that can deal with that.
15:33
Unidentified speaker (speaker_0): So there's, like I said, a lot of different problems in and our our process, our technology. kind of solves those all in kind of a in a in a fulsome way.
15:43
Unidentified speaker (UNKNOWN): Um
15:43
Unidentified speaker (speaker_0): and just adds more optionality that's really required
15:47
Unidentified speaker (UNKNOWN): in
15:47
Unidentified speaker (speaker_0): the protein manufacturing space.
15:49
Unidentified speaker (speaker_1): Yeah. But where, since you started Future Field, which industries are really demanding this? Like which which industries that you think that, you know, currently need a future fields management. manufactured protein than the conventional protein? Like has there been a market expansion that you have undergone as
16:09
Unidentified speaker (speaker_1): you have evolved through the company?
16:12
Unidentified speaker (speaker_0): Yeah, I mean we go we go where the problems are um and and really try to be in tune with the market and the and and the the needs of of the users.
16:23
Unidentified speaker (UNKNOWN): Um
16:23
Unidentified speaker (speaker_0): there are some markets that we're working in now that we didn't even really know needed proteins, you know, two years ago. One example of that is the agrosciences space. Um so think of companies that are developing uh novel GM crops.
16:37
Unidentified speaker (UNKNOWN): So
16:38
Unidentified speaker (speaker_0): they take a gene for uh for some sort of protein and they engineer it into a plant uh and that protein is gonna give it some sort of desired trait, whether it's resistant to drought, disease, insects ironically. Um
16:53
Unidentified speaker (speaker_0): they they uh the regulators require them to show that the product of that gene, which is a protein,
16:59
Unidentified speaker (speaker_1): yeah,
16:59
Unidentified speaker (speaker_0): is gonna be safe once it's introduced into the food supply chain. So for them to do that, for them to get enough of that protein to to do these regulatory and toxicity studies, they need somebody to manufacture it. And so that's kind of an interesting niche that we've found that's been really good for us. Yeah.
17:14
Unidentified speaker (UNKNOWN): It
17:14
Unidentified speaker (speaker_0): just kind of fits with our current capabilities and there's existing problems that you know need to be solved. Um, coming back to to that, um, that is one of the issues that one of our clients has in that space is for them to manufacture enough of their protein for this this study, it would take them 400 weeks because of the yields that they're
17:34
Unidentified speaker (speaker_0): getting. And so the urgency to produce the quantities they need to run that study. it's it's a huge challenge. So that's something that we're working on for them. So
17:42
Unidentified speaker (speaker_1): you're solving for costs, time and capacity.
17:44
Unidentified speaker (speaker_0): Yeah. And again, all those are are are intricately linked. You can't really like hold one out or the other. Like yields inform cost, they inform scale and therefore also your timelines how fast. So
17:57
Unidentified speaker (UNKNOWN): Yeah.
17:57
Unidentified speaker (speaker_0): yeah, there's a lot of different markets and applications
18:00
Unidentified speaker (UNKNOWN): that
18:00
Unidentified speaker (speaker_0): require protein manufacturing. Um we work with clients in the pharmaceutical space, uh drug development, kind of more basic uh biological research. We have industrial applications, one client that's uh in the biofuel space. So there's a lot that require proteins, and that's why I I I mean I tell people that I I really believe that
18:20
Unidentified speaker (speaker_0): recombinant Commonant proteins are some of the most critical products in the world. Um
18:25
Unidentified speaker (UNKNOWN): they
18:25
Unidentified speaker (speaker_0): fundamentally underpin a lot. of society's uh most important uh uh industries. And so it's really important for manufacturing, biomanufacturing to meet the needs of these markets.
18:38
Unidentified speaker (speaker_1): Yeah. Yeah. Well, let's switch gears a little bit. We've talked about how future fields has evolved. We You're are also talking about how the science is evolving as we speak. I want to talk about how you evolved. You started Future Field as a scientist doing your PhD. And at some point you had to become the CEO
18:58
Unidentified speaker (speaker_1): of a company. Tell me, what were some of the hardest lessons you had to learn to step into a different persona?
19:07
Unidentified speaker (UNKNOWN): Yeah,
19:07
Unidentified speaker (speaker_0): I mean, obviously a ton of personal growth was required to uh to get to where we are today and and to where I am. um in in my role. Um when we started the company, I thought I wanted to be a lab rat. I thought I just wanted to be in the lab, build the technology. And so when we started, that's what I was doing.
19:26
Unidentified speaker (UNKNOWN): Um
19:27
Unidentified speaker (speaker_0): and learned a couple of things pretty quickly. One, I'm not a very good scientist to begin with. Uh, you know, managed to get by through grad school, but at the end of the day, I'm I'm not wired like a scientist. Uh I I I'm good at coming up with big ideas, but then the actual execution of those ideas in the lab, there's a lot of people better at it than me. Um so when we
19:47
Unidentified speaker (speaker_0): started hiring people, I realized that I'm like, hey, these guys are better scientists than I am. I probably shouldn't be in here.
19:52
Unidentified speaker (UNKNOWN): Um
19:53
Unidentified speaker (speaker_0): and like I said, I think I'm I'm more geared towards like coming up with
19:57
Unidentified speaker (UNKNOWN): these
19:57
Unidentified speaker (speaker_0): ideas, pitching those ideas, engaging with stakeholders, whether that's customers, investors, et cetera, and really selling selling the vision.
20:04
Unidentified speaker (UNKNOWN): Um,
20:04
Unidentified speaker (speaker_0): and that was a pretty, that wasn't an instant realization. This
20:07
Unidentified speaker (UNKNOWN): was
20:08
Unidentified speaker (speaker_0): over the course
20:08
Unidentified speaker (UNKNOWN): of a year.
20:09
Unidentified speaker (speaker_0): And so um, yeah, then I transitioned into the CEO role, where that became my responsibility. And when that happened, you know, I was still much more um technology focused. I mean, I was I was really all about the technology and I and I and I, you know, I think we had
20:29
Unidentified speaker (speaker_0): this idea that this technology is so great, it's so cool, it's so important. Everybody is going to love it and it's going to sell itself. And of course that's not the case. And and so the learning for me was to kind of stop obsessing over the technology so Do much and start obsessing over the customer and the market and and the problems in the
20:49
Unidentified speaker (speaker_0): market because ultimately you your technology, whoever it is, mine, any any technical founder, technology doesn't matter if it's not serving a purpose in the market, if it's not solving a problem and a meaningful problem at that. Uh, and that was a tough realization for me because again, it was it was like zooming out a little bit
21:09
Unidentified speaker (speaker_0): and and like I said, stop obsessing so much about what we were building and who we were building it for. And again, these were not immediate realizations.
21:17
Unidentified speaker (UNKNOWN): These
21:17
Unidentified speaker (speaker_0): were not like wake up one day and and and you know, solve it. It was kind of like a a a very long, slow growth period. But um that I'd say that was the biggest learning and growth growth factor
21:29
Unidentified speaker (UNKNOWN): for
21:29
Unidentified speaker (speaker_0): me
21:30
Unidentified speaker (UNKNOWN): was
21:30
Unidentified speaker (speaker_0): like to yeah, just start thinking more um more from the lens of the customer and and who our technology is for. Yeah.
21:39
Unidentified speaker (speaker_1): yeah. That was a big probably a lesson or a lesson for you to unlearn a lot of the scientist persona to step into more of execution. Is there any moment where the scientist Matt in you tells you, Oh, I need to perfect this, and the CEO Matt comes and says, just ship it.
21:56
Unidentified speaker (speaker_0): Do
21:56
Unidentified speaker (speaker_1): you go through that?
21:57
Unidentified speaker (speaker_0): No, because that's not how I am. I am I'm a send it kind of guy.
22:01
Unidentified speaker (UNKNOWN): Like
22:01
Unidentified speaker (speaker_0): uh I I'm often uh and that's that's where there's a good counterbalance with my team. Yeah
22:08
Unidentified speaker (UNKNOWN): um
22:08
Unidentified speaker (speaker_0): my co-founder especially, like we're we're very different in that way. Um in that there's kind of like kind of these checks in place uh before we do ship something. But no, and again, this comes back to why I was never a very good scientist to begin with, was because like I'm very much go, go, go, and as soon as we have like kind of
22:28
Unidentified speaker (speaker_0): the the minimum viable data set, I'm ready to ship it. And sometimes it does require,
22:33
Unidentified speaker (speaker_1): you
22:33
Unidentified speaker (speaker_0): know, another replicate or you know another iteration, but I'm very much wired in that way to like as soon as we have what we need to just like keep you know progressing, keep moving the ball forward, um, which suits me very well for
22:46
Unidentified speaker (UNKNOWN): this
22:46
Unidentified speaker (speaker_0): role, but again, requires me to have a team around me to to really make sure that all those boxes are checked and everything is done appropriately uh before we do ship something.
22:58
Unidentified speaker (speaker_1): Any lessons on how you've scaled the team? Like this is not a company where you can just hire a few engineers and start building, right? These are deeply technical research-oriented people. Like what have your lessons been in the team expansion?
23:11
Unidentified speaker (speaker_0): Yeah, I mean there's lots there. I think that any sort of success that we've had to date is because of our team and because of the way we've built our team. I think that that is the single biggest um, I think, X factor that we've had as an organization. Um, and I
23:31
Unidentified speaker (speaker_0): credit my co-founder slash wife uh for a lot of that is just like being very thoughtful about how we built a team. I think we just can't say enough
23:40
Unidentified speaker (UNKNOWN): about
23:40
Unidentified speaker (speaker_0): them. Um and that comes back to like very foundational things like uh you know our values and incorporating being very thoughtful about how we craft our values, uh what they mean, um, and then incorporating that into how we operate, into our the the daily behaviors uh of the team at at
24:00
Unidentified speaker (speaker_0): at work and how we recruit. Um
24:04
Unidentified speaker (speaker_0): every every hire we've had, we're about 40 people right now. And every hire we've had, like Juliana and I, my co-founder, like we do a culture fit interview uh as part of our process. And we weigh that equally with the skill set,
24:17
Unidentified speaker (UNKNOWN): the
24:17
Unidentified speaker (speaker_0): technical skill set. So if we're hiring a scientist, whether we're hiring a scientist Scientists, or you know a controller or or a BD person, they're all going through roughly the same filter at the later stages of the process, which is like, is this a good culture fit?
24:31
Unidentified speaker (speaker_1): Yeah.
24:32
Unidentified speaker (speaker_0): Do they, will they embody our values in in the organization? And uh, like I said, I think that was that's been one of the most important factors for us as we've built a team, which has ultimately been the biggest influence on our success to date.
24:47
Unidentified speaker (speaker_1): Yeah. And then you had an interesting turn, you started the company. in Edmonton, and then you got into the YC program. What did that experience change within you fundamentally? Like, did it move the needle inside?
25:02
Unidentified speaker (UNKNOWN): Um
25:04
Unidentified speaker (UNKNOWN): I
25:04
Unidentified speaker (speaker_0): don't know. I I have uh
25:07
Unidentified speaker (UNKNOWN): I
25:08
Unidentified speaker (speaker_0): have some interesting uh thoughts on this. I mean, transparently, I was not super involved in the YC program. at the time. Um, because this was back in 2020. I was still leading the lab. So I spent a lot of the YC the time we were in the YC program in the lab just building technology and I let my co
25:27
Unidentified speaker (speaker_0): founders kind of be more integrated into the into the program. We were also the first remote batch
25:34
Unidentified speaker (UNKNOWN): because
25:34
Unidentified speaker (speaker_0): this was, you know, peak COVID. So I don't I think we had a bit of a unique experience uh in YC because I don't I think a from what I hear is a lot of the value from from being YC is like um being immersed in the batch and in the cohort and and making connections with with your with the
25:54
Unidentified speaker (speaker_0): other companies. And it was a bit challenging to replicate that in in a kind of a remote setting.
26:01
Unidentified speaker (UNKNOWN): So
26:01
Unidentified speaker (speaker_0): I don't think we built those same connections that you would in a normal um YC context. Um
26:07
Unidentified speaker (speaker_1): did it uh push your ambition just being close to people in the Silicon Valley ecosystem that you've inculcated and brought back to Canada?
26:15
Unidentified speaker (speaker_0): Yeah, I th I think there was like a good healthy injection of like the kind of move fast break thing things sort
26:21
Unidentified speaker (UNKNOWN): of
26:22
Unidentified speaker (speaker_0): mentality of of the valley. Uh I think I that was like it came at a good time for us. Um because you know, we're we're Canadians and we're biologists. So the move fast break things was like not part of our ethos at the time. So I do think it it did introduce a healthy amount of speed and urgency in into our company. But I think the
26:41
Unidentified speaker (speaker_0): biggest thing obviously was the exposure to the the investor community through through YC and post-demo post demo day. I mean, never have we had that. level of exposure and and interest in the company from from the investor side of the table. I mean, coming out of demo day, and it was crazy. We had like
27:01
Unidentified speaker (speaker_0): 82 investor meetings in like 13 days. Um, that and not not like repeat like 82 individual funds uh that we spoke to, um, which was just like a a level of intensity that we've really not ever experienced
27:18
Unidentified speaker (UNKNOWN): uh
27:18
Unidentified speaker (speaker_0): in the organization uh outside of you know the internal project. So that was like obviously a great experience and and I do, I would say like a real big turning point and a real critical moment for us as a company because obviously once being in Canada and Edmonton especially, getting exposure to
27:38
Unidentified speaker (speaker_0): that
27:39
Unidentified speaker (speaker_0): community is really tough. And so through YC, we got plugged in there. And then as you know, it's positive feedback. Like once you get in with one fund, they introduce you to their friends and it snowballs from there. And so I mean I don't I don't know where
27:52
Unidentified speaker (UNKNOWN): we'd
27:52
Unidentified speaker (speaker_0): be if it wasn't for getting into YC if if we'd be where we are today. Because obviously getting that that initial capital was just so critical for us. And you know I I do credit being part of the YC program as as critical to that.
28:06
Unidentified speaker (speaker_1): Do you see like what does the Silicon Valley really underestimate about building a deep tech company in Edmonton? Like what have you a unique advantage of building here?
28:16
Unidentified speaker (speaker_0): Oh, I think there's so many things and I I talk about this all the time. I don't have a I don't have much perspective of building a company prior to COVID because we like we weren't operational until November 2019. So we had about four months of operations before COVID hit. So I don't know if this changed as far
28:36
Unidentified speaker (speaker_0): as like, you know, being able to raise capital internationally
28:41
Unidentified speaker (speaker_0): more easily because of everything kind of went virtual for so long. But I would say, you know, outside of that access to capital, there's just so many advantages to operating. where we do, especially as a biotech company, because, you know, we need space, we need equipment.
28:56
Unidentified speaker (UNKNOWN): Um,
28:57
Unidentified speaker (speaker_0): you know, we we have certain requirements that like say a SaaS company wouldn't have.
29:03
Unidentified speaker (speaker_1): Yeah.
29:03
Unidentified speaker (speaker_0): Uh and a lot of that requires, you know, upfront capital, uh, upfront infrastructure, just to do anything to to do your, you know, seminal experiments to get any sort of proof of concept.
29:13
Unidentified speaker (UNKNOWN): And
29:13
Unidentified speaker (speaker_0): so doing that in Emington, Edmonton was was really advantageous because A, space is very cheap. Yeah. I mean we have 20,000 square feet of space. Uh we pay like you know 12 bucks a square foot. Like it's it's just our operating costs are so much lower than if you were trying to do this in like a tier one
29:33
Unidentified speaker (speaker_0): city in the US. Um, With that payroll is a lot cheaper and and like we can still pay a very competitive salary. And I think we we pay ourselves pretty well. Um, just because cost of living here is so much cheaper than again, say you're in like San Francisco or Boston. Um, so so yeah, compensation scales accordingly to
29:53
Unidentified speaker (speaker_0): cost of living. So our payroll, which is going to be your biggest expense, is relatively a lot less than it would be.
30:01
Unidentified speaker (UNKNOWN): Uh,
30:01
Unidentified speaker (speaker_0): and then the last piece. well, related to that too, is like there's an incredible talent density here that that is overlooked, um, especially for the types of hires that we're looking for, which is
30:11
Unidentified speaker (UNKNOWN): you know,
30:12
Unidentified speaker (speaker_0): a lot of biochemists, geneticists, engineers, et cetera. Um, you know, we get a lot of great talent coming out of the local uh university ecosystem. And we've hired a lot of our team from that. They're like I said, can't say enough about them. Um
30:26
Unidentified speaker (UNKNOWN): and
30:26
Unidentified speaker (speaker_0): then the last piece is all the non-dilutive funding. Um, that's such a huge uh advantage that we have. We've been very fortunate to get a ton of support from various levels of government because again, we need a lot of infrastructure, we need a lot of space, all that costs money, and there's great programs set up exactly for those types of things. So
30:46
Unidentified speaker (speaker_0): our manufacturing site was, you know, supported by every level of government. you know, federal, provincial, and municipal. Um, and so there's just uh an uh an immense um number of programs out there that are really fantastic for supporting those types of projects that we've been able to leverage to the full extent um
31:07
Unidentified speaker (speaker_0): that have been critical for getting us to where we are today.
31:10
Unidentified speaker (speaker_1): The world around future fields is changing very fast. I mean with AI uh it's potentially accelerating our ability to understand biology, to designing a protein. But designing a protein is one thing, but manufacturing it is another. Do you think
31:28
Unidentified speaker (speaker_1): macro in a in a macroeconomic fashion, just because our ability to design new proteins is moving fast, will it outpace our ability to? physically manufacture them?
31:41
Unidentified speaker (speaker_0): Well, uh, yeah, I mean, it already is. And I and I say this all the time. Like, it's crazy now in 2026, like it's it is easier to design design a protein than it is to express it or make it. Um, so I do think that that is cre creating some considerable tailwinds for companies like us because now all of a sudden,
32:00
Unidentified speaker (UNKNOWN): you know,
32:00
Unidentified speaker (speaker_0): that validation, wet lab validation, becomes the bottleneck. Um, you know, it's it's one thing like you can design all these these proteins to do different things, but until you can actually validate that in a biological setting, it you know, it it's you know the design is kind of worthless until you do validate it. And to do that, you need to make the
32:20
Unidentified speaker (speaker_0): protein. Um, therefore you need better expression capabilities. And so that is a a big factor. Um, something that we've integrated into our strategy because transparently our existing technology is actually not a good fit for this because we're more about large scale, uh low cost manufacturing uh
32:40
Unidentified speaker (speaker_0): commercial quantities. And that's not what you need for high throughput. You need low scale, high throughput, large number of samples. So we are developing new tech for that. Um, something that is like, you know, in development and uh it we're extremely excited about. The initial results are are very promising. Um but we
33:00
Unidentified speaker (speaker_0): recognize that that is our gap in our
33:02
Unidentified speaker (UNKNOWN): is that a
33:02
Unidentified speaker (speaker_1): future path for future field where like how big is the market expansion in terms of the universe of proteins that you can solve for? How will you address it?
33:12
Unidentified speaker (speaker_0): Oh yeah. I mean it's endless. And I and I think we've really just become to scratch the surface of what's possible with our system.
33:19
Unidentified speaker (UNKNOWN): Um,
33:19
Unidentified speaker (speaker_0): and that's on on both ends of the spectrum, both in the high throughput capabilities and in the large-scale manufacturing. Um, you know, our our system is six years old. I mean, it's, you know, the the legacy platforms are 10 times as old. So they've had 10 times as amount of uh amount of time to to optimize and perfect. And
33:39
Unidentified speaker (speaker_0): so there's just so many levers we have to improve our system. Again, both on the large scale and on the small scale high throughput. But we are focused a lot right now on on the latter piece of of developing and offering that is meeting more of that the the need for high throughput, small scale uh protein expression.
33:59
Unidentified speaker (speaker_0): And like I said, the the initial results are very promising and we're very excited about that to to bring that offering to the market because again, I think that that is a um a massive need that so many different markets and sectors are going to require. And that that's we're seeing that whether that's in obviously drug development and pharma is
34:19
Unidentified speaker (speaker_0): like the the low hanging fruit there, but we're seeing that even in things like the agri sciences
34:23
Unidentified speaker (UNKNOWN): as well.
34:24
Unidentified speaker (speaker_0): Like everybody everybody wants it you know, better, faster, and and more data. And to do that, we need the systems to keep up.
34:32
Unidentified speaker (speaker_1): Yeah. So there is an ambition of solving for a bigger market, but
34:39
Unidentified speaker (speaker_1): it's not scaling a company that's building software is very different than scaling a company that's real-volved biomanufacturing, right? And it's not that you can just plug another server, uh server to it. Tell me about what does the facility look like right now? Like you've built Instar your biofactory facility in Edmonton.
34:58
Unidentified speaker (speaker_1): Walk me through it. Like what does it take that you can literally demonstrate from building into a lab to now building a large-scale commercial industrial size opportunity? How are you building that opportunity out or how are you building that capacity?
35:14
Unidentified speaker (speaker_0): Yeah. Uh I mean, that's a great question. Um and this was kind of um
35:22
Unidentified speaker (speaker_0): this is this is uh inherent to our system too, is the modularity of our process. So as we think about scaling just raw capacity, there is kind of this sense of just plug another server in. The difference is it's not a server, it's it's a module of of our inset. insects. Now it's kind of the idea is you know, rather than
35:41
Unidentified speaker (speaker_0): having to do these large, discrete incremental steps in scale, which require a lot of capital infrastructure
35:49
Unidentified speaker (UNKNOWN): um
35:50
Unidentified speaker (speaker_0): and and and a lot of investment, yeah, we can actually do it a little bit more seamlessly and a little more um uh uh flexible because again, our our our upstream process, which is the fundamental um bottleneck or the what what dictates capacity in any bioprocess
36:10
Unidentified speaker (UNKNOWN): um
36:11
Unidentified speaker (speaker_0): it is modulo m modular uh so as we do start to scale uh beyond the constraints of our existing facility we're not needing to go and build another entire facility or build a bigger version of what we've done we can actually add just simply add more modules. So to our existing factory, it has
36:31
Unidentified speaker (speaker_0): our upstream, which again is our as our insect raring, and then it has downstream, which is where you go from processing the biomass into the purified product. Um that latter piece, the downstream, is where most of the costs come from in terms of a facility, because that's where you need things to be sterile and very clean. Um
36:51
Unidentified speaker (speaker_0): you have like ISO-certified clean rooms. Um, that's gonna be more costly. Um, but that's not our bottleneck. I mean, we what we have right now uh will serve us for a very long time. The bottleneck is how much space you have for upstream. So for us to add more capacity, again, is is
37:11
Unidentified speaker (speaker_0): gonna be a little bit cheaper uh and a little more seamless than like I said, a lot of the traditional systems. So um right now it's just about, you know, first filling that facility, filling the factory, and then expanding kind of in a more um modular sense beyond um what what we currently have. But it is a a
37:30
Unidentified speaker (speaker_0): modular approach.
37:31
Unidentified speaker (speaker_1): This is just a curious question. What do you find harder, inventing the science or industrializing
37:36
Unidentified speaker (UNKNOWN): it?
37:38
Unidentified speaker (speaker_0): That's a great question.
37:43
Unidentified speaker (UNKNOWN): I
37:43
Unidentified speaker (speaker_0): don't know if I can answer that accurately. I mean, again, I guess it kind of depends on the specific project. Some some it's gonna be more on the science side, uh and some gonna it's gonna be more on the industrial side. Um, and that's just the the nuances of protein manufacturing, from one project to another, from one protein to another, it can change. a lot.
38:03
Unidentified speaker (speaker_0): We have one program right now where it's more on the science side. Like we're having a lot of challenges just expressing the protein and getting it soluble and and purified. Whereas others, it's more about okay, how do we scale this? How
38:14
Unidentified speaker (UNKNOWN): do we
38:15
Unidentified speaker (speaker_0): how do we get it to the quantities that the customer needs?
38:18
Unidentified speaker (UNKNOWN): So
38:18
Unidentified speaker (speaker_0): I think it depends on on the from one program to another and one application to another. Um, but I would say that. uh our technology was always built for industrial scale. It was always built with the the idea of really large scale production. Um and so I think
38:38
Unidentified speaker (speaker_0): that that part once the science is solved uh on the small scale with these with these programs, the the scaling part of it, the industrial side of it um comes more seamlessly.
38:47
Unidentified speaker (speaker_1): And we're going to finish with one big question. It's twenty thirty 2035. Future Fields is successful, not just successful, but really delivered on their mission.
38:58
Unidentified speaker (UNKNOWN): You
38:58
Unidentified speaker (speaker_1): know, you're solving for a problem, the vision which you started, you've delivered. What exists in the world in 2035 that would have not existed if Future Fields was never there?
39:11
Unidentified speaker (UNKNOWN): Yes.
39:11
Unidentified speaker (speaker_0): I mean, our our big Here Harry Audacious goal, like our 2035. goal is to positively impact a billion lives by enabling novel products to reach the market. So if we look, you know, nine years from now into 2035, there is a a new, a novel bioproduct that exists on
39:31
Unidentified speaker (speaker_0): the market, or multiple novel bioproducts that exist on the market that wouldn't have been there if we if we didn't exist. And that's because of you know, the the protein manufacturing capability. So that could be a novel crop that
39:45
Unidentified speaker (speaker_0): feeds the world more sustainably, or that could be a novel therapeutic that can cures some disease that required a protein in the process. That's kind of how we measure success or or our our goal for that that 10-year 10 market. year mark is like how many lives
40:05
Unidentified speaker (speaker_0): have we positively impacted. That can be hard to quantify, of course, but um that's okay. I think it's it's more so about the the ethos of of what we're trying to do, which is you know always rooted in in impact.
40:17
Unidentified speaker (speaker_1): Yeah. Yeah. Well Matt, I think that's a wonderful place to wrap up the conversation. This has been genuinely very inspiring and I have learned so much about fruit flies that ever, ever in my life, now every time I will see a fruit fly, I'm going to really thank that fruit fly. But thank you so much. I really hope you deliver
40:37
Unidentified speaker (speaker_1): in your mission. You have the right ingredients, the right ethos, and also a mission that you want to make a positive impact on the world. Thank you so much for joining the Further Faster podcast. If you would like to hear more such stories, hear more such stories about founders who are changing the world with one company at a time, make sure that you
40:57
Unidentified speaker (speaker_1): are tuned in, you like, subscribe, share, and share it with a scientist friend that you might know. Thank you again, and thank you, Matt.
41:05
Unidentified speaker (speaker_0): Thank
41:05
Unidentified speaker (UNKNOWN): you.
This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-UD-IQ3_S.gguf. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.
All insights